“Learn on the progress in the field of cytokines”

Christian Klein, Department Head Cancer Immunotherapy Discovery 3 & Site Head, Roche Innovation Center Zurich

“The cytokine immunotherapy field is undergoing a resurgence phase. A plethora of new information and the lessons learned from previous experience are important to design better treatment strategies.  This meeting addresses exactly that.”

Khursheed Anwar, Executive Vice President and CSO, Celsion Corporation

“This meeting represents a great opportunity to learn how dynamic and exciting the cytokine therapy field currently is.”  

Ignacio Moraga, Principal Investigator, PhD, University of Dundee

“It is important to examine the potential.  This meeting will provide detailed presentations and discussion about the promising new approaches for using  cytokines to improve the antitumor efficacy of checkpoint inhibitor based immunotherapy.”

Michael B. Atkins, Deputy Director, Georgetown Lombardi Comprehensive Cancer Center Scholl Professor and Vice Chair, Department of Oncology, Georgetown University Medical Center

“Cytokines are immunomodulatory proteins that have been considered for pharmaceutical applications in the treatment of cancer patients and other types of disease. There is a growing interest in the use of engineered cytokine products as anticancer drugs, capable of boosting the action of T cells and natural killer (NK) cells against tumors, alone or in combination with immune checkpoint inhibitors.”

Roberto De Luca, Head of therapeutic antibodies, Philogen

“Good opportunity to learn above novel approaches to improve the therapeutic window of cytokine drugs”

Michael Schmidt, Chief Scientific Officer, Ankyra Therapeutics